Nanoengineered Platform-Based Microenvironment-Triggered Immunotherapy in Cancer Treatment.

IF 3.3 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY
Namdev Dhas, Ritu Kudarha, Sanjay Kulkarni, Soji Soman, Prerana D Navti, Jahnavi Kulkarni, Amrita Arup Roy, Viola Colaco, Ruchira Raychaudhuri, Ashutosh Gupta, Chandrakantsing Pardeshi, Dipak Bari, Ruchi Tiwari, Jayvadan Patel, Sudheer Moorkoth, Srinivas Mutalik
{"title":"Nanoengineered Platform-Based Microenvironment-Triggered Immunotherapy in Cancer Treatment.","authors":"Namdev Dhas, Ritu Kudarha, Sanjay Kulkarni, Soji Soman, Prerana D Navti, Jahnavi Kulkarni, Amrita Arup Roy, Viola Colaco, Ruchira Raychaudhuri, Ashutosh Gupta, Chandrakantsing Pardeshi, Dipak Bari, Ruchi Tiwari, Jayvadan Patel, Sudheer Moorkoth, Srinivas Mutalik","doi":"10.31083/j.fbl2910349","DOIUrl":null,"url":null,"abstract":"<p><p>The immune system and cancer cells interact intricately during the growth of tumors, and the dynamic interplay between immune activation and suppression greatly influences the cancer outcome. Natural killer cells (NK), cytotoxic T lymphocytes (CTLs) and Dendritic cells (DC), employ diverse mechanisms, to combat cancer. However, the challenges posed by factors such as chronic inflammation and the immunosuppressive tumor microenvironment (TME) often hinder immune cells' ability to detect and eliminate tumors accurately. Immunotherapy offers a promising approach, reprogramming the immune system to target and eliminating cancer cells while minimizing side effects, enhancing immune memory, and lowering the risk of metastasis and relapse compared to traditional treatments like radiation and surgery. Nanotechnology presents a potential solution by enabling safer, more efficient drug delivery through nanoparticles. These nanoengineered drugs can be tailored for controlled activation and release. Improving TME characters holds potential for enhancing personalized immunotherapy and addressing T cell availability issues within tumor sites, particularly when combined with existing therapies. This review discusses TMEs and the strategies to overcome immunosuppression in TME, and various immune cell-based strategies to improve antitumor response. It also focuses on the strategies for constructing microenvironment responsive nanoplatforms based upon the factors present at higher levels in TME like acidic pH, hypoxia facilitated by poor oxygen supply, higher expression of certain enzymes, and other factors such light, ultrasound and magnetic field. Combination immune therapies combined with immunotherapy include photodynamic therapy, photothermal therapy, chemotherapy, gene therapy and radiotherapy, revealing a high level of anticancer activity in comparison to a single therapy, enhancing immunogenicity, promoting therapeutic efficacy, and lowering metastasis. In conclusion, cancer immunotherapy is a potential technique to combat cancer cells and boost the immune system, hindering their growth and recurrence. In order to prevent cancer, it helps the immune system target cancer cells selectively and strengthens its long-term memory. Clinical trials are extending the application of immunotherapy and identifying strategies to improve the immune system tumor-fighting capabilities. Immunotherapy has enormous promise and gives hope for more successful cancer treatment.</p>","PeriodicalId":73069,"journal":{"name":"Frontiers in bioscience (Landmark edition)","volume":"29 10","pages":"349"},"PeriodicalIF":3.3000,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in bioscience (Landmark edition)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31083/j.fbl2910349","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The immune system and cancer cells interact intricately during the growth of tumors, and the dynamic interplay between immune activation and suppression greatly influences the cancer outcome. Natural killer cells (NK), cytotoxic T lymphocytes (CTLs) and Dendritic cells (DC), employ diverse mechanisms, to combat cancer. However, the challenges posed by factors such as chronic inflammation and the immunosuppressive tumor microenvironment (TME) often hinder immune cells' ability to detect and eliminate tumors accurately. Immunotherapy offers a promising approach, reprogramming the immune system to target and eliminating cancer cells while minimizing side effects, enhancing immune memory, and lowering the risk of metastasis and relapse compared to traditional treatments like radiation and surgery. Nanotechnology presents a potential solution by enabling safer, more efficient drug delivery through nanoparticles. These nanoengineered drugs can be tailored for controlled activation and release. Improving TME characters holds potential for enhancing personalized immunotherapy and addressing T cell availability issues within tumor sites, particularly when combined with existing therapies. This review discusses TMEs and the strategies to overcome immunosuppression in TME, and various immune cell-based strategies to improve antitumor response. It also focuses on the strategies for constructing microenvironment responsive nanoplatforms based upon the factors present at higher levels in TME like acidic pH, hypoxia facilitated by poor oxygen supply, higher expression of certain enzymes, and other factors such light, ultrasound and magnetic field. Combination immune therapies combined with immunotherapy include photodynamic therapy, photothermal therapy, chemotherapy, gene therapy and radiotherapy, revealing a high level of anticancer activity in comparison to a single therapy, enhancing immunogenicity, promoting therapeutic efficacy, and lowering metastasis. In conclusion, cancer immunotherapy is a potential technique to combat cancer cells and boost the immune system, hindering their growth and recurrence. In order to prevent cancer, it helps the immune system target cancer cells selectively and strengthens its long-term memory. Clinical trials are extending the application of immunotherapy and identifying strategies to improve the immune system tumor-fighting capabilities. Immunotherapy has enormous promise and gives hope for more successful cancer treatment.

基于纳米工程平台的微环境触发免疫疗法在癌症治疗中的应用。
在肿瘤生长过程中,免疫系统和癌细胞之间存在着错综复杂的相互作用,免疫激活和抑制之间的动态相互作用在很大程度上影响着癌症的预后。自然杀伤细胞(NK)、细胞毒性 T 淋巴细胞(CTL)和树突状细胞(DC)采用多种机制来对抗癌症。然而,慢性炎症和免疫抑制性肿瘤微环境(TME)等因素往往会阻碍免疫细胞准确检测和消除肿瘤的能力。与放疗和手术等传统治疗方法相比,免疫疗法提供了一种前景广阔的方法,它能重新编程免疫系统,使其瞄准并消灭癌细胞,同时最大限度地减少副作用,增强免疫记忆,降低转移和复发的风险。纳米技术通过纳米颗粒实现了更安全、更高效的药物输送,从而提供了一种潜在的解决方案。这些纳米工程药物可以量身定制,以控制活化和释放。改善 TME 特性有可能增强个性化免疫疗法,并解决肿瘤部位的 T 细胞可用性问题,尤其是在与现有疗法相结合时。本综述讨论了 TME 和克服 TME 中免疫抑制的策略,以及各种基于免疫细胞的改善抗肿瘤反应的策略。综述还重点介绍了根据肿瘤组织中存在的较高水平因素(如酸性 pH 值、因氧气供应不足而导致的缺氧、某些酶的较高表达)以及其他因素(如光、超声波和磁场)构建微环境响应纳米平台的策略。与免疫疗法相结合的联合免疫疗法包括光动力疗法、光热疗法、化疗、基因疗法和放疗,与单一疗法相比,这些疗法具有较高的抗癌活性,可增强免疫原性,提高疗效,减少转移。总之,癌症免疫疗法是对抗癌细胞、增强免疫系统、阻碍癌细胞生长和复发的潜在技术。为了预防癌症,它可以帮助免疫系统选择性地靶向癌细胞,并增强其长期记忆。临床试验正在扩大免疫疗法的应用范围,并确定提高免疫系统抗肿瘤能力的策略。免疫疗法前景广阔,为更成功地治疗癌症带来了希望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信